Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study.
Adult SMA
Clinical trial
Longitudinal progression
MUNIX
Outcome measures
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
06
09
2020
accepted:
19
11
2020
revised:
19
11
2020
pubmed:
4
1
2021
medline:
22
6
2021
entrez:
3
1
2021
Statut:
ppublish
Résumé
The aim of this study was the comprehensive characterisation of longitudinal clinical, electrophysiological and neuroimaging measures in type III and IV adult spinal muscular atrophy (SMA) with a view to propose objective monitoring markers for future clinical trials. Fourteen type III or IV SMA patients underwent standardised assessments including muscle strength testing, functional evaluation (SMAFRS and MFM), MUNIX (abductor pollicis brevis, APB; abductor digiti minimi, ADM; deltoid; tibialis anterior, TA; trapezius) and quantitative cervical spinal cord MRI to appraise segmental grey and white matter atrophy. Patients underwent a follow-up assessment with the same protocol 24 months later. Longitudinal comparisons were conducted using the Wilcoxon-test for matched data. Responsiveness was estimated using standardized response means (SRM) and a composite score was generated based on the three most significant variables. Significant functional decline was observed based on SMAFRS (p = 0.019), pinch and knee flexion strength (p = 0.030 and 0.027), MUNIX and MUSIX value in the ADM (p = 0.0006 and 0.043) and in TA muscle (p = 0.025). No significant differences were observed based on cervical MRI measures. A significant reduction was detected in the composite score (p = 0.0005, SRM = -1.52), which was the most responsive variable and required a smaller number of patients than single variables in the estimation of sample size for clinical trials. Quantitative strength testing, SMAFRS and MUNIX readily capture disease progression in adult SMA patients. Composite multimodal scores increase predictive value and may reduce sample size requirements in clinical trials.
Identifiants
pubmed: 33388927
doi: 10.1007/s00415-020-10332-5
pii: 10.1007/s00415-020-10332-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1792-1802Références
Lefebvre S, Bürglen L, Reboullet S et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155–165
pubmed: 7813012
Munsat TL, Davies KE (1992) International SMA consortium meeting (26-28 June 1992, Bonn, Germany). Neuromuscul Disord NMD 1992(2):423–428
Wadman RI, Wijngaarde CA, Stam M et al (2018) Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c–4. Eur J Neurol 25:512–518
pubmed: 29194869
Wang CH, Finkel RS, Bertini ES et al (2007) Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 22:1027–1049
pubmed: 17761659
Mercuri E, Lucibello S, Pera MC et al (2019) Long-term progression in type II spinal muscular atrophy: a retrospective observational study. Neurology 93:e1241–e1247
pubmed: 31451515
pmcid: 7011866
Piepers S, van den Berg LH, Brugman F et al (2008) A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol 255:1400–1404
pubmed: 18575920
Deymeer F, Serdaroglu P, Parman Y, Poda M (2008) Natural history of SMA IIIb: muscle strength decreases in a predictable sequence and magnitude. Neurology 71:644–649
pubmed: 18725590
Bonati U, Holiga Š, Hellbach N et al (2017) Longitudinal characterization of biomarkers for spinal muscular atrophy. Ann Clin Transl Neurol 4:292–304
pubmed: 28491897
pmcid: 5420809
Montes J, McDermott MP, Mirek E et al (2018) Ambulatory function in spinal muscular atrophy: age-related patterns of progression. PLoS ONE 13:e0199657
pubmed: 29944707
pmcid: 6019250
Mercuri E, Darras BT, Chiriboga CA et al (2018) Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625–635
pubmed: 29443664
Mendell JR, Al-Zaidy S, Shell R et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713–1722
pubmed: 29091557
Montes J, Gordon AM, Pandya S, De Vivo DC, Kaufmann P (2009) Clinical outcome measures in spinal muscular atrophy. J Child Neurol 24:968–978
pubmed: 19509409
Finkel R, Bertini E, Muntoni F, Mercuri E, ENMC SMA Workshop Study Group (2014) 209th ENMC International Workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7–9 November 2014, Heemskerk, The Netherlands. In: Neuromuscular disorder, vol 25. Elsevier, The Netherlands, pp 593–602
Kariyawasam DST, D’Silva A, Lin C, Ryan MM, Farrar MA (2019) Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy. Front Neurol 10:898
pubmed: 31481927
pmcid: 6709682
Montes J, Glanzman AM, Mazzone ES et al (2015) Spinal muscular atrophy functional composite score: a functional measure in spinal muscular atrophy. Muscle Nerve 52:942–947
pubmed: 25846132
Seferian AM, Moraux A, Canal A et al (2015) Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial. PLoS ONE 10:e0121799
pubmed: 25861036
pmcid: 4393256
Nandedkar SD, Nandedkar DS, Barkhaus PE, Stalberg EV (2004) Motor unit number index (MUNIX). IEEE Trans Biomed Eng 51:2209–2211
pubmed: 15605872
Querin G, Lenglet T, Debs R et al (2018) The motor unit number index (MUNIX) profile of patients with adult spinal muscular atrophy. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 129:2333–2340
Querin G, El Mendili M-M, Lenglet T et al (2018) The spinal and cerebral profile of adult spinal-muscular atrophy: a multimodal imaging study. NeuroImage Clin 21:101618
pubmed: 30522974
pmcid: 6413472
Mercuri E, Finkel RS, Muntoni F et al (2018) Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 28:103–115
pubmed: 29290580
Dunaway Young S, Montes J, Kramer SS et al (2016) Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve 54:836–842
pubmed: 27015431
Montes J, Dunaway Young S, Mazzone ES et al (2019) Nusinersen improves walking distance and reduces fatigue in later-onset SMA. Muscle Nerve 60:409–414
pubmed: 31298747
pmcid: 6771553
Vuillerot C, Payan C, Iwaz J, Ecochard R, Bérard C (2013) MFM spinal muscular atrophy study group. responsiveness of the motor function measure in patients with spinal muscular atrophy. Arch Phys Med Rehabil 94:1555–1561
pubmed: 23380348
Bertini E, Dessaud E, Mercuri E et al (2017) Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:513–522
pubmed: 28460889
Allenbach Y, Benveniste O, Decostre V et al (2012) Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. Neuromuscul Disord NMD 22:980–986
pubmed: 22738680
Servais L, Deconinck N, Moraux A et al (2013) Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients. Neuromuscul Disord 23:139–148
pubmed: 23219352
Chabanon A, Seferian AM, Daron A et al (2018) Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS ONE 13:e0201004
pubmed: 30048507
pmcid: 6062049
Decostre V, Canal A, Ollivier G et al (2015) Wrist flexion and extension torques measured by highly sensitive dynamometer in healthy subjects from 5 to 80 years. BMC Musculoskelet Disord 16:4
pubmed: 25636264
pmcid: 4322806
Moraux A, Canal A, Ollivier G et al (2013) Ankle dorsi- and plantar-flexion torques measured by dynamometry in healthy subjects from 5 to 80 years. BMC Musculoskelet Disord 14:104
pubmed: 23522186
pmcid: 3617997
Martin AR, De Leener B, Cohen-Adad J et al (2017) A novel MRI biomarker of spinal cord white matter injury: T2*-weighted white matter to gray matter signal intensity ratio. AJNR Am J Neuroradiol 38:1266–1273
pubmed: 28428212
pmcid: 7960075
De Leener B, Lévy S, Dupont SM et al (2017) SCT: Spinal Cord Toolbox, an open-source software for processing spinal cord MRI data. NeuroImage 145:24–43
pubmed: 27720818
Gros C, De Leener B, Badji A et al (2019) Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. NeuroImage 184:901–915
pubmed: 30300751
Husted JA, Cook RJ, Farewell VT, Gladman DD (2000) Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 53:459–468
pubmed: 10812317
Oldenburg D, Guberina N, Stolte B et al (2019) Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy. Neuroradiology Epub 61:565–574
Hogrel J-Y, Payan CA, Ollivier G et al (2007) Development of a French isometric strength normative database for adults using quantitative muscle testing. Arch Phys Med Rehabil 88:1289–1297
pubmed: 17908571
Hogrel JY, Ollivier G, Desnuelle C (2006) Manual and quantitative muscle testing in neuromuscular disorders. How to assess the consistency of strength measurements in clinical trials? Rev Neurol 162:427–436
pubmed: 16585903
Fathi D, Mohammadi B, Dengler R, Böselt S, Petri S, Kollewe K (2016) Lower motor neuron involvement in ALS assessed by motor unit number index (MUNIX): long-term changes and reproducibility. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 127:1984–1988
Bas J, Delmont E, Fatehi F et al (2018) Motor unit number index correlates with disability in Charcot–Marie-tooth disease. Clin Neurophysiol 129:1390–1396
pubmed: 29729594
Fatehi F, Grapperon A-M, Fathi D, Delmont E, Attarian S (2018) The utility of motor unit number index: a systematic review. Neurophysiol Clin Clin Neurophysiol 48:251–259
Neuwirth C, Nandedkar S, Stålberg E et al (2011) Motor Unit Number Index (MUNIX): reference values of five different muscles in healthy subjects from a multi-centre study. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 122:1895–1898
Neuwirth C, Braun N, Claeys KG et al (2018) Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: real world experience from 27 centres. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 129:1756–1762
Neuwirth C, Burkhardt C, Alix J et al (2016) Quality control of motor unit number index (MUNIX) measurements in 6 muscles in a single-subject “Round-Robin” setup. PLoS ONE 11:e0153948
pubmed: 27135747
pmcid: 4852906
Lingor P, Weber M, Camu W et al (2019) ROCK-ALS: protocol for a randomized, placebo-controlled, double-blind phase IIa trial of safety, tolerability and efficacy of the Rho kinase (ROCK) inhibitor Fasudil in amyotrophic lateral sclerosis. Front Neurol 10:293
pubmed: 30972018
pmcid: 6446974
Swash M (2019) Reading the palm with MUNIX: a “reversed split hand” in spinal muscular atrophy. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 130:305–306
Günther R, Neuwirth C, Koch JC et al (2019) Motor Unit Number Index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 130:315–319
Chipika RH, Finegan E, Li Hi Shing S, Hardiman O, Bede P (2019) Tracking a fast-moving disease: longitudinal markers, monitoring, and clinical trial endpoints in ALS. Front Neurol 10:229
pubmed: 30941088
pmcid: 6433752
Ard MC, Raghavan N, Edland SD (2015) Optimal composite scores for longitudinal clinical trials under the linear mixed effects model. Pharm Stat 14:418–426
pubmed: 26223663
pmcid: 5132034